Catharina T G Roos1, Veerle A B van den Bogaard1, Marcel J W Greuter2, Rozemarijn Vliegenthart2, Ewoud Schuit3, Johannes A Langendijk1, Arjen van der Schaaf1, Anne P G Crijns1, John H Maduro4. 1. University of Groningen, University Medical Center Groningen, Department of Radiation Oncology, The Netherlands. 2. University of Groningen, University Medical Center Groningen, Center for Medical Imaging, The Netherlands. 3. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, The Netherlands. 4. University of Groningen, University Medical Center Groningen, Department of Radiation Oncology, The Netherlands. Electronic address: j.h.maduro@umcg.nl.
Abstract
BACKGROUND AND PURPOSE: The main objective of this study was to test whether pre-treatment coronary artery calcium (CAC) was associated with the cumulative incidence of acute coronary events (ACE) among breast cancer (BC) patients treated with postoperative radiotherapy (RT). MATERIAL AND METHODS: The study population consisted of 939 consecutive female BC patients treated with RT. The association between CAC and ACE was tested using Cox-proportional hazard models. Known risk factors for ACE and the mean heart dose (MHD), collected from three-dimensional computed tomography planning data, were tested for confounding. RESULTS: CAC scores varied from 0 to 2,859 (mean 27.3). The 9-year cumulative incidence of ACE was 3.2%, this was significantly associated with the pre-treatment CAC score. After correction for confounders, age, history of ischemic heart disease, diabetes, Body Mass Index ≥30, MHD, hypercholesterolemia and hypertension, the hazard ratio for ACE for the low and the combined intermediate and high CAC score category were 1.42 (95%CI: 0.49-4.17; p = 0.519) and 4.95 (95%CI: 1.69-14.53; p = 0.004) respectively, compared to the CAC zero category. CONCLUSIONS: High pre-treatment CAC is associated with ACE in BC patients treated with postoperative RT, even after correction for confounding factors such as MHD.
BACKGROUND AND PURPOSE: The main objective of this study was to test whether pre-treatment coronary artery calcium (CAC) was associated with the cumulative incidence of acute coronary events (ACE) among breast cancer (BC) patients treated with postoperative radiotherapy (RT). MATERIAL AND METHODS: The study population consisted of 939 consecutive female BC patients treated with RT. The association between CAC and ACE was tested using Cox-proportional hazard models. Known risk factors for ACE and the mean heart dose (MHD), collected from three-dimensional computed tomography planning data, were tested for confounding. RESULTS: CAC scores varied from 0 to 2,859 (mean 27.3). The 9-year cumulative incidence of ACE was 3.2%, this was significantly associated with the pre-treatment CAC score. After correction for confounders, age, history of ischemic heart disease, diabetes, Body Mass Index ≥30, MHD, hypercholesterolemia and hypertension, the hazard ratio for ACE for the low and the combined intermediate and high CAC score category were 1.42 (95%CI: 0.49-4.17; p = 0.519) and 4.95 (95%CI: 1.69-14.53; p = 0.004) respectively, compared to the CAC zero category. CONCLUSIONS: High pre-treatment CAC is associated with ACE in BC patients treated with postoperative RT, even after correction for confounding factors such as MHD.
Authors: Konrad Pieszko; Aakash D Shanbhag; Mark Lemley; Mark Hyun; Serge Van Kriekinge; Yuka Otaki; Joanna X Liang; Daniel S Berman; Damini Dey; Piotr J Slomka Journal: Eur J Nucl Med Mol Imaging Date: 2022-06-25 Impact factor: 10.057
Authors: José Luis Zamorano; Christer Gottfridsson; Riccardo Asteggiano; Dan Atar; Lina Badimon; Jeroen J Bax; Daniela Cardinale; Antonella Cardone; Elizabeth A M Feijen; Péter Ferdinandy; Teresa López-Fernández; Chris P Gale; John H Maduro; Javid Moslehi; Torbjørn Omland; Juan Carlos Plana Gomez; Jessica Scott; Thomas M Suter; Giorgio Minotti Journal: Eur J Heart Fail Date: 2020-10-02 Impact factor: 15.534
Authors: Michael E Layoun; Eric H Yang; Joerg Herrmann; Cezar A Iliescu; Juan C Lopez-Mattei; Kostas Marmagkiolis; Matthew J Budoff; Maros Ferencik Journal: Curr Treat Options Oncol Date: 2019-05-06
Authors: Roxanne Gal; Sanne G M van Velzen; Maartje J Hooning; Marleen J Emaus; Femke van der Leij; Madelijn L Gregorowitsch; Erwin L A Blezer; Sofie A M Gernaat; Nikolas Lessmann; Margriet G A Sattler; Tim Leiner; Pim A de Jong; Arco J Teske; Janneke Verloop; Joan J Penninkhof; Ilonca Vaartjes; Hanneke Meijer; Julia J van Tol-Geerdink; Jean-Philippe Pignol; Desirée H J G van den Bongard; Ivana Išgum; Helena M Verkooijen Journal: JAMA Oncol Date: 2021-07-01 Impact factor: 31.777
Authors: Juan C Lopez-Mattei; Eric H Yang; Maros Ferencik; Lauren A Baldassarre; Susan Dent; Matthew J Budoff Journal: JACC CardioOncol Date: 2021-12-21
Authors: L B van den Oever; D S Spoor; A P G Crijns; R Vliegenthart; M Oudkerk; R N J Veldhuis; G H de Bock; P M A van Ooijen Journal: J Med Syst Date: 2022-03-25 Impact factor: 4.920
Authors: Lindsay L Puckett; Shahryar G Saba; Sonia Henry; Stacey Rosen; Elise Rooney; Samaria L Filosa; Philip Gilbo; Karalyn Pappas; Alison Laxer; Katherine Eacobacci; Amitha N Kapyur; Justin Robeny; Samantha Musial; Anisha Chaudhry; Rahul Chaudhry; Martin L Lesser; Adam Riegel; Sariah Ramoutarpersaud; Navid Rahmani; Amar Shah; Vivian Papas; Toluwani Dawodu; Jessica Charlton; Jonathan P S Knisely; Lucille Lee Journal: Cancer Med Date: 2021-07-10 Impact factor: 4.452